Multipharma Group has announced the launch of Inceptua Medicines Access, which is a new business unit providing access to pre-approval and unlicensed medicines and will be led by a team of specialist industry experts.
Global medicines
The business unit will include three divisions: Inceptua Medicines Access Pharma — engaging with biopharmaceutical clients to provide controlled pre-approval access programmes to medicines; Inceptua Medicines Access Healthcare — sourcing and supplying unlicensed medicines on an on-demand basis for hospitals, pharmacists and physicians; Inceptua Medicines Access Consulting — offering strategy support services to biopharmaceutical clients.
“The sector has not adapted nor kept pace with the needs of the biopharmaceutical industry, healthcare professionals and their patients worldwide,” said Mark Corbett, executive vice president, Inceptua Medicines Access. “Current demand combined with a complex and dynamic regulatory and political landscape means we need a new way of thinking about ethical and compliant access to pre-approval and unlicensed medicines.”
Inceptua Medicines Access offers a holistic approach to meet areas of unmet medical need, such as patients seeking access to investigational treatments in advance of regulatory approval.
